Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SUPAC-MR guidance increases allowable Level 1 content variation from 2% to 5%.

This article was originally published in The Tan Sheet

Executive Summary

FDA SUPAC-MR GUIDANCE INCREASES CONTENT VARIATION FROM 2% TO 5% for Level 1 release-controlling excipients for all extended- and delayed-release solid oral dosage forms. The Oct. 6 Scale-Up and Post-Approval Changes final guidance for Modified-Release Solid Oral Dosage Forms states that for Level 1 components and composition changes, "the total additive effect of all release-controlling excipient changes should not be more than 5% [by weight] of the total release-controlling excipients in the original approved formulation." Component and composition changes would be filed in a company annual report.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS087685

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel